BlackRock Real Assets acquires a solar power portfolio from a Taiwan renewable energy specialist, marking a number of firsts for the firm
Wrongly dismissed as a mere communications upgrade, data infrastructure is a new asset sub-class unto itself. A growing field of investors is recognizing the evolving opportunity set
Green Investment Group (GIG), a global clean energy investment platform managed by Macquarie Capital, has acquired Conergy Asia & ME, a Singapore-based solar power developer owned by Goldman Sachs Asset Management and Tennenbaum Capital Partners.
Wattle Hill RHC, a private equity firm that targets Australian businesses with products and services that appeal to Chinese consumers, has won board approval for a A$189.7 million ($138 million) privatization of honey producer Capilano Honey.
KKR has agreed to buy a 60% stake in India-based environmental services provider Ramky Enviro Engineers (REEL) for $530 million via a combination of primary and secondary investments valuing the company at $925 million.
True North has agreed to acquire the Indian orthopedics and pain management business of drug maker Glenmark Pharmaceuticals at a valuation of INR6.4 billion ($91.8 million).
Japanese private equity firm NSSK has acquired hospitality business Hotel Castle Inn Group for an undisclosed sum.
BlackRock Real Assets has agreed to acquire a 28-project solar power portfolio in Taiwan for an undisclosed sum.
Private equity firms are participating in late-stage rounds in Asia’s technology space as they look to gain a toehold in start-ups with the potential to transform economies. But do the valuations make sense?
True North aimed to set Indian seed maker Seedworks apart from its competitors by leveraging digital technology. Two years into its investment the private equity firm is seeing its initiatives pay off
The growing influence of technology across every industry is forcing PE firms to review approaches to investment. Ensuring the right people have the right information sits at the heart of these efforts
TPG Capital has agreed to acquire the Asia pathology assets of Australian hospital operator Healthscope for A$279 million ($206 million), giving it control of 39 pathology laboratories across Singapore, Malaysia, and Vietnam.
The Longreach Group has agreed to acquire a majority stake in Fujitsu Component from its parent company and will launch a tender offer to buy the business outright at a valuation of JPY13.7 billion ($123.6 million).
Seven years after its privatization of Yageo Corp was blocked, KKR is back pursuing a $1.56 billion bid for LYC Chemical Corp. The initial response from regulators has been positive
Indian hospitals are increasingly attractive for private equity investors. GPs can thrive in the space with a well-defined growth strategy that takes local market requirements into account
TPG Capital and Abu Dhabi Investment Authority (ADIA) have teamed up with India-listed UPL Corporation on a $4.2 billion acquisition of Arysta LifeScience, an agricultural chemicals manufacturer that originated in Japan.
KKR is pursuing its first Taiwan privatization since 2011 – when the acquisition of Yageo Corp. was blocked, prompting questions about the government’s attitude towards PE buyouts – with a NT$47.8 billion ($1.56 billion) bid for LCY Chemical Corp.
Standard Chartered Private Equity (SCPE) has invested an undisclosed amount in Indian online travel company Travel Boutique Online (TBO) to acquire a stake held by South African internet conglomerate Naspers.
LeapFrog Investments has acquired a majority stake in India-base healthcare industry supplier Ascent Meditech for an undisclosed sum.
Lakeshore Capital has taken a controlling stake in domestic drug manufacturer Devakam Apothecary Hall, owner of the Namman Muay analgesic cream brand, for an undisclosed amount.
Quadrant Private Equity has agreed to buy a portfolio of candy brands manufactured in New Zealand from Nestle for an undisclosed sum.
Chinese mid-market private equity buyout firm Jade Invest has acquired domestic pest control company Guardian Hygiene Service for an undisclosed sum.
China’s Yungfeng Capital has teamed up with Shenzhen-based Hybio Pharmaceutical to acquire diversified German biopharmaceuticals company AMW for an undisclosed sum.
Nissan Motor has abandoned plans to sell its electric battery operations and production facilities to GSR Capital because the Chinese private equity firm didn’t have sufficient funds to complete the transaction.